Atezolizumab, given in combination with enzalutamide, did not show improvement in overall survival (OS) or cancer control compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC), resulting in early termination of the phase III IMbassador250 study.

Platinum-based neoadjuvant chemotherapy appears to be beneficial in patients with bulky regional lymph node metastases from penile cancer, with nearly 50 percent responding to treatment and about 16 percent achieving a pathological complete response, results of a systematic review and meta-analysis have shown.

“Ultimately, the robustness of these observations should be interpreted with an awareness of the inherent limitations of deriving data from a collection of small, heterogeneous series,” the investigators said.

Atezolizumab, given in combination with enzalutamide, did not show improvement in overall survival (OS) or cancer control compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC), resulting in early termination of the phase III IMbassador250 study.